Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec;8(12):1711-21.
doi: 10.1586/erc.10.160.

Prevention of venous thromboembolism in obesity

Andrew L Freeman  1 , Robert C Pendleton, Matthew T Rondina
Affiliations
Review

Prevention of venous thromboembolism in obesity

Andrew L Freeman et al. Expert Rev Cardiovasc Ther. 2010 Dec.

Abstract

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in hospitalized patients. Where appropriate, evidence-based methods of prophylaxis are implemented and the burden of VTE can be reduced substantially. Obesity, including morbid obesity, is associated with a high risk of VTE and, unfortunately, fixed doses of US FDA-approved anticoagulant regimens, including unfractionated heparins, low-molecular-weight heparins and factor Xa inhibitors, may not provide optimal VTE prophylaxis in these patients. Although the data are still limited, a rapidly growing body of literature and cumulative evidence suggests that anticoagulant dose adjustments in morbidly obese patients may optimize pharmacodynamic activity and reduce VTE risk. With the prevalence of morbid obesity continuing to rise, more high-quality clinical data are needed to better understand the pathobiology of VTE in obesity and provide effective, yet safe, prevention strategies.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am. J. Med. 2009;122:1077–1084. - PubMed
    1. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch. Intern. Med. 2007;167:1471–1475. - PMC - PubMed
    1. Anderson FA, Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. 1991;151:933–938. - PubMed

    1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:381S–453S.. •• Guidelines summarizing general recommendations for venous thromboembolism (VTE) prophylaxis. Includes a thorough discussion of prophylaxis considerations in orthopedic, surgical and medical patients.

    1. Berlot G, Calderan C, Vergolini A, et al. Pulmonary embolism in critically ill patients receiving antithrombotic prophylaxis: a clinical-pathologic study. J. Crit. Care. 2010 (Epub ahead of print). - PubMed

Website

    1. Surgeon General news releases. [Accessed 29 July 2010];Acting Surgeon General Issues ‘Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism’: Office of the Surgeon General Website. www.surgeongeneral.gov/news/pressreleases/pr20080915.html.

Publication types

MeSH terms